Bioventus BVS Estimates

NASDAQ BVS
$13.64 -0.19 (-1.41%)
As of: Sep 9, 2026 · 3:59 PM EDT
Analyst Estimates

Bioventus Inc. Revenue Estimates

Periods 26
Next Period Q3 26
Consensus 145.30 M

Analysts expect Bioventus Inc. to report revenue of 145.30 M for Q3 26, against a range of 137.97 M to 152.62 M. The most recent reported quarter, Q2 26, came in at 153.21 M, a 6.2% miss against the 163.30 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 138.96 M153.64 M123.88 M147.66 M138.65 M157.90 M132.09 M153.21 M--------
High Estimate 145.37 M155.67 M122.62 M154.21 M152.02 M159.53 M144.52 M179.10 M152.62 M182.98 M150.33 M167.00 M160.88 M183.56 M164.07 M188.11 M
Low Estimate 130.59 M143.76 M109.23 M128.75 M134.02 M135.55 M132.02 M147.49 M137.97 M166.73 M124.14 M137.53 M144.97 M163.73 M145.23 M175.98 M
Consensus Estimate 137.98 M149.72 M115.92 M141.48 M143.02 M147.54 M138.27 M163.30 M145.30 M174.85 M137.23 M152.27 M152.92 M173.64 M154.65 M182.04 M
Analyst Estimates

Bioventus Inc. Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q3 26
Consensus 0.16

Analysts expect Bioventus Inc. to report earnings per share of 0.16 for Q3 26, against a range of 0.15 to 0.17. The most recent reported quarter, Q2 26, came in at 0.22, a 4.8% beat against the 0.21 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 0.060.150.080.210.150.240.150.22--------
High Estimate 0.020.090.020.180.110.230.070.220.170.250.150.260.230.370.170.29
Low Estimate 0.020.070.020.140.090.190.070.200.150.210.130.240.190.330.150.27
Consensus Estimate 0.020.080.020.160.100.210.070.210.160.230.140.250.210.350.160.28